NEWS

 

A new orphan disease-focused company

MSBi Valorisation announces the creation of Laurent Pharmaceuticals, a new biopharmaceutical company specializing in rare diseases
 
Montreal, QC, Canada – April 22, 2013
MSBi Valorisation (MSBiV), McGill University (McGill) and the Research Institute of the McGill University Health Centre (RI-MUHC) today announced the creation of Laurent Pharmaceuticals, a start-up pharmaceutical company specializing in drug development for orphan diseases. Laurent has a lead program focusing on Fenretinide, an intensively explored but never commercialized synthetic retinoid derivative, as novel therapy for Cystic Fibrosis (CF) patients suffering from lung infection with Pseudomonas aeruginosa.
 

Events

Laurent Pharmaceuticals to participate at BIO Digital 2021, June 10-11 & 14-18, 2021